Skip to main content
. 2011 Nov 14;4:46. doi: 10.1186/1756-8722-4-46

Table 1.

Efficacy, cardiotoxicity and early death rate of CAG in AML


Study (ref) Year No.
Patients *
Median age (range) Aclarubicin dosage AML No. AML CR No. AML CR % OS (m) (range) CT No. ED No.

Yamada [14] 1995 18 44 (18-74) 10-14 mg/m2 × 4d 18 15 83 17 (2-28) 0 0

Saito [35] 1995 18 NR(18-74) 10 or 14 mg/m2 × 4d 18 15 83 15 (1-35) 1 0

Saito [36] 1996 28 NR(18-74) 10 or 14 mg/m2 × 4d 28 24 86 17 (1-47) 0 0

Tabata [37] 1998 76 NR(60-83) 14 mg/m2 × 4d 8 5 63 NA NA NA

Saito [38] 2000 69 51 (15-82) 10 or 14 mg/m2 × 4d 51 31 62 NA 0 0

Hirayama [39] 2003 18 NR(65-80) 14 mg/m2 × 4d 9 6 67 9 (1-43) 0 1

Li [26] 2005 112 47 (15-81) 14 mg/m2 × 4d or 8 mg/m2 × 8d 99 44 44 NA 0 1

Kong [40] 2005 20 NR(18-80) 10-14 mg/m2 × 4d 20 11 55 NA 0 0

Yang [41] 2005 16 NR(60-82) 6 mg/m2 × 8d 16 9 56 NA 0 1

Huang [25] 2005 30 NR(15-67) 5-7 mg/m2 × 8d 30 22 73 NA 0 1

Qian [19] 2005 21 NR(15-81) 10 mg/d × 8d 21 14 67 NA 0 2

Xie [42] 2006 25 NR(55-78) 10 mg/m2 × 4d 25 12 48 NA 0 3

Liu [27] 2006 13 NR(18-77) 10-14 mg/m2 × 4d 13 5 39 NA 0 0

Wang [43] 2006 11 NR(25-72) 10 mg/m2 × 8d 11 4 36 NA 0 0

Wu [44] 2007 15 NR(60-84) 7 mg/m2 × 8d 15 8 53 NA 1 1

Qian [20] 2007 50 65 (60-81) 10 mg/d × 8d 50 29 58 14 (1-60) 0 4

Su [29] 2007 16 NR 20 mg/d × 4d 16 9 56 NA 0 0

Guo [45] 2007 8 NR(18-56) 5-7 mg/m2×5d 8 4 50 NA 0 0

Chen [46] 2008 75 NR(60-85) 10 mg/d × 8d 34 23 68 NA 0 0

Sang [47] 2008 45 NR(60-73) 7 mg/m2 × 8d 23 9 39 NA 0 1

Bian [48] 2008 46 NR(18-72) 10-14 mg/m2 × 4d 26 20 77 NA 0 0

Chai [49] 2009 17 NR 15 mg/m2×7d 17 8 47 NA 0 0

Zhu [50] 2009 50 NR(15-69) 10 mg/d × 8d 30 14 47 NA 0 1

Ni [51] 2009 70 NR(22-85) 14 mg/m2 × 4d 61 34 56 28 (1-89) 0 3

Feng [52] 2010 32 NR(60-74) 5-7 mg/m2 × 8d 16 9 56 NA 0 0

Ma [28] 2010 31 NR(19-71) 14 mg/m2 × 4d 26 14 54 NA 0 0

Li [53] 2010 38 NR(19-61) 5-7 mg/m2 × 8d 18 14 78 NA 0 0

Liang [54] 2010 54 NR(17-82) 5-7 mg/m2 × 8d 39 21 54 NA 1 7

Suzushima [55] 2010 68 76 (60-88) 14 mg/m2 × 4d 68 33 49 9 (0-56) NA 15

Abbreviations: AML: acute myeloid leukemia; Ref: references; NA: not available; NR: not reported; *: total number of AML and MDS patients; m: month; CR: complete remission; OS: overall survival; CT: cardiotoxicity; ED: early death; CAG: cytarabine, aclarubicin and G-CSF.